British Biotech and ImmunoGen Begin
Selected Abstract
British Biotech and ImmunoGen Begin Patient Enrollment for the Phase I/II Trial of BB-10901/huN901-DM1 in Small Cell Lung Cancer.
CAMBRIDGE, Mass., May 29 /PRNewswire/ -- British Biotech (LSE: BBG; Nasdaq: BBIOY) and ImmunoGen Inc. (Nasdaq: IMGN) today began patient enrollment for the Phase I/II clinical study to evaluate the safety, pharmacokinetic profile and biological activity of the Tumor-Activated Prodrug (TAP), ... May 29, 2001; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
British Biotech and ImmunoGen Begin Patient Enrollment for the Phase I/II Trial of BB-10901/huN901-DM1 in Small Cell Lung Cancer.
|
